Mometasona Generis (Mometasone Furoate Anhydrous)

Mometasone furoate binds to glucocorticoid receptors in the cells lining the nasal mucosa. This interaction modifies gene transcription, leading to decreased production of inflammatory cytokines and reduced recruitment of immune cells, which together diminish swelling and irritation in the nasal passages.

The specific dosing regimen for Mometasona Generis is determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms, and clinical response. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using the product.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Mometasona Generis contains mometasone furoate, which is a high‑potency intranasal corticosteroid with a favorable safety profile when used as directed. Compared with lower‑potency agents such as fluticasone or budesonide, mometasone may achieve symptom control at lower daily doses, but the choice of therapy should be individualized by the prescriber.

Store Mometasona Generis at room temperature, preferably below 25 °C. Keep the spray bottle in its original packaging, protect it from excessive moisture and direct sunlight, and ensure the cap is tightly closed when not in use.

Mometasona Generis is administered as a nasal spray. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and spray the prescribed number of sprays while breathing in gently. The process is then repeated in the other nostril if directed by the prescriber.

Serious risks, though rare, include fungal infection of the nasal mucosa, severe or persistent nosebleeds, adrenal suppression leading to systemic glucocorticoid effects, and severe allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience any of these symptoms.

Mometasona Generis should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients with active, untreated nasal infections or recent nasal surgery unless cleared by a physician.